The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104.
 
Heloisa P. Soares
Consulting or Advisory Role - Advanced Accelerator Applications; AstraZeneca; Exelixis; Ipsen; QED Therapeutics; TerSera
 
Katherine A Guthrie
No Relationships to Disclose
 
Syed A. Ahmad
No Relationships to Disclose
 
Mary Kay Washington
Consulting or Advisory Role - Takeda
 
Brian Hemendra Ramnaraign
No Relationships to Disclose
 
Nitya Prabhakar Raj
Consulting or Advisory Role - Ipsen
Research Funding - Corcept Therapeutics (Inst); Novartis (Inst); Xencor (Inst)
 
Carole Seigel
No Relationships to Disclose
 
Shay Bellasea
No Relationships to Disclose
 
E. Gabriela Chiorean
Consulting or Advisory Role - Bayer; BioNTech; Ipsen; Legend Biotech; Noxxon Pharma; Noxxon Pharma; Pfizer; SOBI
Research Funding - AADi (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Corcept Therapeutics (Inst); FibroGen; Halozyme (Inst); Ignyta (Inst); Merck (Inst); Rafael Pharmaceuticals (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Ipsen; Legend Biotech
 
Arvind Dasari
Consulting or Advisory Role - Advanced Accelerator Applications; Hutchison MediPharma; Ipsen; Lexicon; Novartis; Voluntis
Research Funding - Eisai; Guardant Health; Hutchison MediPharma; Ipsen; Merck; Novartis
 
Jonathan R. Strosberg
Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; Novartis
Speakers' Bureau - Ipsen
Research Funding - Novartis
 
Cathy Eng
Consulting or Advisory Role - Bayer Health; Gilead/Forty Seven; GlaxoSmithKline; Hookipa Biotech; Mirati Therapeutics; natera; Pfizer
Research Funding - Elevar Therapeutics; Hutchison China Meditech; Merck; Pfizer
 
Philip Agop Philip
Honoraria - Array BioPharma; AstraZeneca; Bayer; Blueprint Medicines; Celgene; Ipsen; Merck; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals